{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+of+Care+%28SoC%29+Therapy&page=29", "query": { "intervention": "Standard of Care (SoC) Therapy", "page": 29 }, "page_size": 10 }, "pagination": { "page": 29, "page_size": 10, "total_count": 767, "total_pages": 77, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+of+Care+%28SoC%29+Therapy&page=30&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+of+Care+%28SoC%29+Therapy&page=28&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T15:43:16.034Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04935359", "title": "Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "NIS793", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 511, "start_date": "2021-09-30", "completion_date": "2024-08-13", "has_results": true, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-10-17T15:43:16.034Z", "location_count": 9, "location_summary": "Fayetteville, Arkansas • Los Angeles, California • Orlando, Florida + 6 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04935359" }, { "nct_id": "NCT04302025", "title": "A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Alectinib", "type": "DRUG" }, { "name": "Entrectinib", "type": "DRUG" }, { "name": "Vemurafenib", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Pralsetinib", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "SBRT", "type": "DRUG" }, { "name": "Resection", "type": "PROCEDURE" }, { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Divarasib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 99, "start_date": "2020-11-06", "completion_date": "2030-05-30", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-17T15:43:16.034Z", "location_count": 38, "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 28 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04302025" }, { "nct_id": "NCT01208142", "title": "Toe Walker Gait Trial", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Gait" ], "interventions": [ { "name": "standard of care treatment", "type": "OTHER" }, { "name": "Ankle Flexion Dynasplint", "type": "DEVICE" } ], "intervention_types": [ "OTHER", "DEVICE" ], "sponsor": "Dynasplint Systems, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Year to 18 Years" }, "enrollment_count": 10, "start_date": "2010-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-08-12", "last_synced_at": "2026-10-17T15:43:16.034Z", "location_count": 2, "location_summary": "Columbus, Ohio • Lubbock, Texas", "locations": [ { "city": "Columbus", "state": "Ohio" }, { "city": "Lubbock", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01208142" }, { "nct_id": "NCT05740566", "title": "Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Small Cell Lung Cancer (SCLC)" ], "interventions": [ { "name": "Tarlatamab", "type": "DRUG" }, { "name": "Lurbinectedin", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" }, { "name": "Amrubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 509, "start_date": "2023-05-31", "completion_date": "2028-03-26", "has_results": true, "last_update_posted_date": "2026-01-05", "last_synced_at": "2026-10-17T15:43:16.034Z", "location_count": 25, "location_summary": "Mobile, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 19 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Santa Monica", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05740566" }, { "nct_id": "NCT05284747", "title": "EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Cardiovascular Disease", "Myocardial Infarction", "Stroke", "Coronary Revascularization" ], "interventions": [ { "name": "Evolocumab", "type": "DRUG" }, { "name": "Routine Lipid Management", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 6019, "start_date": "2022-10-26", "completion_date": "2027-05-29", "has_results": false, "last_update_posted_date": "2025-10-06", "last_synced_at": "2026-10-17T15:43:16.034Z", "location_count": 81, "location_summary": "Birmingham, Alabama • Fairhope, Alabama • Huntsville, Alabama + 73 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fairhope", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Flagstaff", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05284747" }, { "nct_id": "NCT06934538", "title": "First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Unresectable Metastatic Colorectal Cancer", "Unresectable Locally Advanced Colorectal Cancer" ], "interventions": [ { "name": "STC-1010 + IS regimen + SOC therapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Brenus Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 90, "start_date": "2025-06-17", "completion_date": "2029-06", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-17T15:43:16.034Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06934538" }, { "nct_id": "NCT00825435", "title": "Coronary CT Angiography in Acute Chest Pain is a Cost Effective Risk Stratification Strategy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Chest Pain" ], "interventions": [ { "name": "Coronary CT Angiogram", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "35 Years", "maximum_age": null, "sex": "ALL", "summary": "35 Years and older" }, "enrollment_count": 60, "start_date": "2008-10", "completion_date": "2012-09", "has_results": false, "last_update_posted_date": "2019-09-17", "last_synced_at": "2026-10-17T15:43:16.034Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00825435" }, { "nct_id": "NCT02498717", "title": "Preliminary Review of Cold and Active Compression Therapy for Traumatic Calcaneus or Ankle Fractures", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Ankle Fractures" ], "interventions": [ { "name": "GameReady", "type": "DEVICE" }, { "name": "RICE", "type": "OTHER" } ], "intervention_types": [ "DEVICE", "OTHER" ], "sponsor": "AdventHealth", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 55, "start_date": "2015-06-03", "completion_date": "2017-07-26", "has_results": false, "last_update_posted_date": "2018-02-15", "last_synced_at": "2026-10-17T15:43:16.034Z", "location_count": 1, "location_summary": "Orlando, Florida", "locations": [ { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02498717" }, { "nct_id": "NCT07116174", "title": "A Prospective Clinical Study to Evaluate the Effectiveness and Safety of Xcell Amnio MatrixTM (XAM) in the Management of Chronic Non-healing DFUs", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Diabetic Foot Ulcer (DFU)" ], "interventions": [ { "name": "Xcell Amnio Matrix", "type": "BIOLOGICAL" }, { "name": "Standard of Care (SOC)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "New Horizon Medical Solutions", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 135, "start_date": "2025-08-15", "completion_date": "2026-08-15", "has_results": false, "last_update_posted_date": "2026-03-31", "last_synced_at": "2026-10-17T15:43:16.034Z", "location_count": 3, "location_summary": "Fresno, California • San Diego, California • Dallas, Texas", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07116174" }, { "nct_id": "NCT05306574", "title": "A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "Telitacicept", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Vor Biopharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "12 Years to 70 Years" }, "enrollment_count": 91, "start_date": "2022-06-20", "completion_date": "2025-01-06", "has_results": false, "last_update_posted_date": "2026-01-09", "last_synced_at": "2026-10-17T15:43:16.034Z", "location_count": 12, "location_summary": "Anniston, Alabama • Mission Hills, California • Orange, California + 9 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Mission Hills", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Thousand Oaks", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05306574" } ] }